Hormones and Cancer

, Volume 2, Issue 3, pp 170–181 | Cite as

Progesterone Receptor-B Induction of BIRC3 Protects Endometrial Cancer Cells from AP1-59-Mediated Apoptosis

  • Nikki L. Neubauer
  • Erin C. Ward
  • Parin Patel
  • Zhenxiao Lu
  • Irene Lee
  • Leen J. Blok
  • Payman Hanifi-Moghaddam
  • Julian Schink
  • J. Julie Kim


Progesterone is a growth inhibitory hormone in the endometrium. While progestins can be used for the treatment of well-differentiated endometrial cancers, resistance to progestin therapy occurs for reasons that remain unclear. We have previously demonstrated that progesterone receptors (PR) A and B differentially regulate apoptosis in response to overexpression of the forkhead transcription factor, FOXO1. In this study, we further examined the PR-isoform-dependent cellular response to the AKT pathway. Treatment of PRA and PRB-expressing Ishikawa cells (PRA14, PRB23), with an AKT inhibitor API-59CJ-OMe (API-59) promoted apoptosis in the presence and absence of the ligand, R5020 preferentially in PRA14 cells. Upon PR knockdown using small interfering RNA, an increase in apoptosis was observed in PRB23 cells treated with API-59 with or without R5020 while there was no influence in PRA14 cells. Using an apoptosis-focused real-time PCR array, genes regulated by API-59 and R5020 were identified both common and unique to PRA14 and PRB23 cells. BIRC3 was identified as the only gene regulated by R5020 which occurred only in PRB cells. Knockdown of BIRC3 in PRB23 cells promoted a decrease in cell viability in response to API-59 + R5020. Furthermore, the important role of inhibitors of apoptosis (IAPs) in the PRB23 cells to promote cell survival was demonstrated using an antagonist to IAPs, a second mitochondria-derived activator of caspase (Smac also known as DIABLO) mimetic. Treatment of PRB23 cells with Smac mimetic increased apoptosis in response to API-59 + R5020. In summary, our findings indicate a mechanism by which PRB can promote cell survival in the setting of high AKT activity in endometrial cancer cells.


Endometrial cancer Progesterone receptor BIRC3 

Supplementary material

12672_2011_65_MOESM1_ESM.ppt (154 kb)
Supplementary Figure 1Venn diagram shows the pattern of overlap of genes regulated at least 2-fold in a statistically significant manner. Comparisons were A R5020-treated PRA14 and PRB23 cells, B API-59-treated PRA14 and PRB23 cells, C API-59 + R5020 (A + R)-treated PRA14 and PRB23 cells, D R5020, API-59, and or A + R treatment in PRA14 cells, E R5020, API-59, and/or A + R treatment in PRB23 cells. (PPT 153 kb)


  1. 1.
    Clarke CL, Sutherland RL (1990) Progestin regulation of cellular proliferation. Endocr Rev 11(2):266–301PubMedCrossRefGoogle Scholar
  2. 2.
    Creasman WT (1997) Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 24(1 Suppl 1):S1-140–S141-150Google Scholar
  3. 3.
    Munstedt K, Grant P, Woenckhaus J, Roth G, Tinneberg HR (2004) Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol 2:24. doi:10.1186/1477-7819-2-24 PubMedCrossRefGoogle Scholar
  4. 4.
    Chiva L, Lapuente F, Gonzalez-Cortijo L, Carballo N, Garcia JF, Rojo A, Gonzalez-Martin A (2008) Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 111(2 Suppl):S101–S104. doi:10.1016/j.ygyno.2008.07.056 PubMedCrossRefGoogle Scholar
  5. 5.
    Kim JJ, Chapman-Davis E (2010) Role of progesterone in endometrial cancer. Semin Reprod Med 28(1):81–90. doi:10.1055/s-0029-1242998 PubMedCrossRefGoogle Scholar
  6. 6.
    Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9(5):1603–1614PubMedGoogle Scholar
  7. 7.
    Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP (2000) The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 20(9):3102–3115PubMedCrossRefGoogle Scholar
  8. 8.
    Smid-Koopman E, Blok LJ, Kuhne LC, Burger CW, Helmerhorst TJ, Brinkmann AO, Huikeshoven FJ (2003) Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J Soc Gynecol Investig 10(1):49–57PubMedCrossRefGoogle Scholar
  9. 9.
    Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB (2006) Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol 20(11):2656–2670. doi:10.1210/me.2006-0105 PubMedCrossRefGoogle Scholar
  10. 10.
    Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB (1993) Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7(10):1256–1265PubMedCrossRefGoogle Scholar
  11. 11.
    Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T (1995) Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol 16(4):254–260PubMedCrossRefGoogle Scholar
  12. 12.
    Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL (2001) Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61(11):4576–4582PubMedGoogle Scholar
  13. 13.
    Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK (1998) Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res 58(9):1860–1865PubMedGoogle Scholar
  14. 14.
    Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112(3):537–542. doi:10.1016/j.ygyno.2008.10.032 PubMedCrossRefGoogle Scholar
  15. 15.
    Dai D, Wolf DM, Litman ES, White MJ, Leslie KK (2002) Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62(3):881–886PubMedGoogle Scholar
  16. 16.
    Ueda M, Fujii H, Yoshizawa K, Abe F, Ueki M (1996) Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro. Jpn J Cancer Res 87(5):524–533PubMedGoogle Scholar
  17. 17.
    Hanekamp EE, Kuhne LM, Grootegoed JA, Burger CW, Blok LJ (2004) Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice. Endocr Relat Cancer 11(4):831–841. doi:10.1677/erc.1.00844 PubMedCrossRefGoogle Scholar
  18. 18.
    Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, Singh DK, Buttin BM, Schink JC, Kim JJ (2008) The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 149(4):1942–1950. doi:10.1210/en.2007-0756 PubMedCrossRefGoogle Scholar
  19. 19.
    Hecht JL, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24(29):4783–4791. doi:10.1200/JCO.2006.06.7173 PubMedCrossRefGoogle Scholar
  20. 20.
    Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57(21):4736–4738PubMedGoogle Scholar
  21. 21.
    Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E (2008) Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 13(2):259–271. doi:10.1007/s10495-007-0165-6 PubMedCrossRefGoogle Scholar
  22. 22.
    Jin X, Gossett DR, Wang S, Yang D, Cao Y, Chen J, Guo R, Reynolds RK, Lin J (2004) Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer 91(10):1808–1812. doi:10.1038/sj.bjc.6602214 PubMedCrossRefGoogle Scholar
  23. 23.
    Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S, Sato S, Akeshima R, Terakawa N (2001) Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 7(4):892–895PubMedGoogle Scholar
  24. 24.
    Gagnon V, St-Germain ME, Parent S, Asselin E (2003) Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1. Int J Oncol 23(3):803–810PubMedGoogle Scholar
  25. 25.
    Nishida M, Kasahara K, Oki A, Satoh T, Arai Y, Kubo T (1996) Establishment of eighteen clones of Ishikawa cells. Hum Cell 9(2):109–116PubMedGoogle Scholar
  26. 26.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262 PubMedCrossRefGoogle Scholar
  27. 27.
    Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harran P, Wang X (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12(5):445–456. doi:10.1016/j.ccr.2007.08.029 PubMedCrossRefGoogle Scholar
  28. 28.
    Hoekstra AV, Ward EC, Hardt JL, Lurain JR, Singh DK, Buttin BM, Schink JC, Kim JJ (2008) Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol Oncol 108(3):609–618. doi:10.1016/j.ygyno.2007.11.007 PubMedCrossRefGoogle Scholar
  29. 29.
    Tang HJ, Jin X, Wang S, Yang D, Cao Y, Chen J, Gossett DR, Lin J (2006) A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol Oncol 100(2):308–317. doi:10.1016/j.ygyno.2005.08.044 PubMedCrossRefGoogle Scholar
  30. 30.
    Harding MM, Grummitt AR (2003) 9-Hydroxyellipticine and derivatives as chemotherapy agents. Mini Rev Med Chem 3(2):67–76PubMedCrossRefGoogle Scholar
  31. 31.
    Di Nezza LA, Jobling T, Salamonsen LA (2003) Progestin suppresses matrix metalloproteinase production in endometrial cancer. Gynecol Oncol 89(2):325–333PubMedCrossRefGoogle Scholar
  32. 32.
    Saito T, Mizumoto H, Tanaka R, Satohisa S, Adachi K, Horie M, Kudo R (2004) Overexpressed progesterone receptor form B inhibit invasive activity suppressing matrix metalloproteinases in endometrial carcinoma cells. Cancer Lett 209(2):237–243. doi:10.1016/j.canlet.2003.12.017 PubMedCrossRefGoogle Scholar
  33. 33.
    Moe BG, Vereide AB, Orbo A, Sager G (2009) High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis. Anticancer Res 29(4):1053–1058PubMedGoogle Scholar
  34. 34.
    Cervantes M, Gonzalez-Vidal MD, Ruelas R, Escobar A, Morali G (2002) Neuroprotective effects of progesterone on damage elicited by acute global cerebral ischemia in neurons of the caudate nucleus. Arch Med Res 33(1):6–14PubMedCrossRefGoogle Scholar
  35. 35.
    Gonzalez-Vidal MD, Cervera-Gaviria M, Ruelas R, Escobar A, Morali G, Cervantes M (1998) Progesterone: protective effects on the cat hippocampal neuronal damage due to acute global cerebral ischemia. Arch Med Res 29(2):117–124PubMedGoogle Scholar
  36. 36.
    Morrissy S, Xu B, Aguilar D, Zhang J, Chen QM (2010) Inhibition of apoptosis by progesterone in cardiomyocytes. Aging Cell 9(5):799–809. doi:10.1111/j.1474-9726.2010.00619.x PubMedCrossRefGoogle Scholar
  37. 37.
    Gonzalez SL, Labombarda F, Deniselle MC, Mougel A, Guennoun R, Schumacher M, De Nicola AF (2005) Progesterone neuroprotection in spinal cord trauma involves up-regulation of brain-derived neurotrophic factor in motoneurons. J Steroid Biochem Mol Biol 94(1–3):143–149. doi:10.1016/j.jsbmb.2005.01.016 PubMedCrossRefGoogle Scholar
  38. 38.
    Labombarda F, Gonzalez Deniselle MC, De Nicola AF, Gonzalez SL (2010) Progesterone and the spinal cord: good friends in bad times. Neuroimmunomodulation 17(3):146–149. doi:10.1159/000258709 PubMedCrossRefGoogle Scholar
  39. 39.
    Vares G, Ory K, Lectard B, Levalois C, Altmeyer-Morel S, Chevillard S, Lebeau J (2004) Progesterone prevents radiation-induced apoptosis in breast cancer cells. Oncogene 23(26):4603–4613. doi:10.1038/sj.onc.1207601 PubMedCrossRefGoogle Scholar
  40. 40.
    Chen H, Wu Z, Li J, Chen R, Yu Y, Xu L, Shuai J, Tu YT (2009) Effect of progesterone on gonococci-induced apoptosis and respiratory burst of human polymorphonuclear leukocytes in vitro. Int J Dermatol 48(9):1011–1016. doi:10.1111/j.1365-4632.2009.04177.x PubMedCrossRefGoogle Scholar
  41. 41.
    Quiles I, Millan-Arino L, Subtil-Rodriguez A, Minana B, Spinedi N, Ballare C, Beato M, Jordan A (2009) Mutational analysis of progesterone receptor functional domains in stable cell lines delineates sets of genes regulated by different mechanisms. Mol Endocrinol 23(6):809–826. doi:10.1210/me.2008-0454 PubMedCrossRefGoogle Scholar
  42. 42.
    Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277(7):5209–5218. doi:10.1074/jbc.M110090200 Google Scholar
  43. 43.
    Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY, Stanculescu A (2009) Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 69(23):8918–8925. doi:10.1158/0008-5472.CAN-09-2608 PubMedCrossRefGoogle Scholar
  44. 44.
    Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, Frasor J (2010) Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm Canc 1:127–135. doi:10.1007/s12672-010-0018-6 CrossRefGoogle Scholar
  45. 45.
    Runnebaum IB, Bruning A (2005) Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2. Clin Cancer Res 11(17):6325–6332. doi:10.1158/1078-0432.CCR-05-0182 PubMedCrossRefGoogle Scholar
  46. 46.
    Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M et al (2009) Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 100(5):903–913. doi:10.1111/j.1349-7006.2009.01112.x PubMedCrossRefGoogle Scholar
  47. 47.
    Petersen SL, Peyton M, Minna JD, Wang X (2010) Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci USA 107(26):11936–11941. doi:10.1073/pnas.1005667107 PubMedCrossRefGoogle Scholar
  48. 48.
    Chen DJ, Huerta S (2009) Smac mimetics as new cancer therapeutics. Anticancer Drugs 20(8):646–658. doi:10.1097/CAD.0b013e32832ced78 PubMedCrossRefGoogle Scholar
  49. 49.
    Dai Y, Lawrence TS, Xu L (2009) Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res 1(1):1–15PubMedGoogle Scholar
  50. 50.
    Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, Bardeesy N et al (2010) Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 70(7):2852–2861. doi:10.1158/0008-5472.CAN-09-3892 PubMedCrossRefGoogle Scholar
  51. 51.
    Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, Bolognesi M et al (2010) Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer 102(12):1707–1716. doi:10.1038/sj.bjc.6605687 PubMedCrossRefGoogle Scholar
  52. 52.
    Orzaez M, Gortat A, Mondragon L, Perez-Paya E (2009) Peptides and peptide mimics as modulators of apoptotic pathways. ChemMedChem 4(2):146–160. doi:10.1002/cmdc.200800246 PubMedCrossRefGoogle Scholar
  53. 53.
    Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, Wang L (2010) Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 17(10):1645–1654. doi:10.1038/cdd.2010.44 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Nikki L. Neubauer
    • 1
  • Erin C. Ward
    • 2
  • Parin Patel
    • 2
  • Zhenxiao Lu
    • 2
  • Irene Lee
    • 2
  • Leen J. Blok
    • 3
  • Payman Hanifi-Moghaddam
    • 3
  • Julian Schink
    • 1
  • J. Julie Kim
    • 2
  1. 1.Division of Gynecologic OncologyNorthwestern UniversityChicagoUSA
  2. 2.Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer CenterNorthwestern UniversityChicagoUSA
  3. 3.Department of Obstetrics and GynecologyErasmus University Medical CenterRotterdamThe Netherlands

Personalised recommendations